Please find enclosed press release for Q2FY27 financial results.

27th October, 2026 (1) BSE Limited (2) National Stock Exchange of India Limited Listing Department Listing Department Phiroze Jeejeebhoy Towers, Exchange Plaza, 5th floor, Dalal Street, Plot no. C/1, G Block, Bandra Kurla Complex, Mumbai - 400 001 Bandra (East), Mumbai - 400 051 Scrip Code: 500087 Scrip Symbol: CIPLA (3) SOCIETE DE LA BOURSE DE LUXEMBOURG Societe Anonyme 35A Boulevard Joseph II, L-1840 Luxembourg Sub: Press Release – Q2FY27 Financial Results Dear Sir / Madam, Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing herewith the Press Release for Q2FY27 Financial Results dated 27th October, 2026. Kindly take the above information on record. Thanking you, Yours faithfully, For Cipla Limited Rajendra Chopra Company Secretary Encl: As above Prepared by: Simona Dsouza Cipla Ltd. Regd. Office - Cipla House, Peninsula Business Park, Ganpatrao Kadam Marg, Lower Parel, Mumbai-400 013, India P +91 22 41916000 W www.cipla.com E-mail contactus@cipla.com Corporate Identity Number L24239MH1935PLC002380 ` Q2 FY27 Results Consistent Sequential Growth in Revenue and EBITDA Reflecting Sustained Business Momentum Income from Operations EBITDA PAT INR 1,388 Cr INR 878 Cr INR 7,404 Cr FY27: (18.7%) (11.9%) Mumbai, October 27, 2026: Cipla Limited (BSE: 500087, NSE: CIPLA) today announced its unaudited consolidated financial results for the quarter ended September 30th, 2026. Key Highlights for the Quarter ▪ One-India: The business recorded highest quarterly sales with a solid growth of 12% YoY. ▪ North America: Delivered quarterly revenue of $ 172 Mn. ▪ One Africa: South Africa private business grew 1.3x faster than the market*. ▪ Emerging Markets and Europe: Delivered quarterly revenue of $ 101 Mn, despite geopolitical uncertainties. ▪ R&D investments: Stood at INR 423 Cr, accounting for 5.7% of sales, directed largely toward product filings and key development programs. ▪ Strong net cash: Net cash position of INR 9,823 Cr; Debt primarily includes lease liabilities and working capital requirements. *Market data as per IQVIA MAT Aug’26 “We are pleased to share that we continue to make considerable progress across our focused markets. In Q2FY27, we delivered global revenues of INR 7,404 Cr with a sequential growth of 4% QoQ, while EBITDA margin expanded by 200 basis points QoQ to 18.7%. Our One-India business grew at solid 12% YoY. Branded Prescription business delivered a robust growth, with key therapies outpacing the market. The U.S. business posted revenue of $ 172 Mn during the quarter, continuing its sequential growth trajectory. We expect North America performance to remain supported by our upcoming product pipeline. South Africa private market business continued to outperform the market, growing approximately 1.3x faster than the market. We continue to focus on sustained growth in our core businesses, improving productivity, strengthening our pipeline in order to serve patients with trusted, high-quality medicines” Achin Gupta MD and Global CEO, Cipla Ltd For Queries Contact: Corporate Communications Investor Relations Cipla Ltd. Heena Kanal Diksha Maheshwari Cipla House, CorpComm@cipla.com Investor.Relations@cipla.com Peninsula Business Park, Ganpatrao Kadam Marg, Lower Parel, Mumbai-400013 Market Updates ❖ One India Business Branded Prescription: Delivered market# growth of 15%. Key therapies like Respiratory, Urology, Cardiac, Anti-diabetes and Dermatology grew at strong double-digit market# growth. Trade Generics: The business delivered a strong double-digit QoQ growth. Expanding portfolio remains a key growth driver, with 15+ new launches this quarter, addressing specific patient needs. Consumer Health: Anchor brands of Nicotex, Omnigel and Cipladine maintained leadership positions in their respective market segments. ❖ North America Delivered quarterly revenue of $ 172 Mn, which represents a $10 Mn improvement versus previous quarter. Albuterol ranked No. 1 in the overall U.S. Albuterol MDI market, with a 22% market share*. The quarter was marked by key strategic milestones in the U.S., including the FDA approval of gAdvair Diskus, the first dry powder inhaler approval from Cipla's U.S. manufacturing network. The business entered an exclusive partnership with Qilu Pharmaceutical for the commercialization of a Keytruda biosimilar, strengthening its presence in complex respiratory therapies and oncology biosimilars. ❖ One Africa In South Africa Private Market secondary growth was at 6.5% versus the market** growth of 5.0%. The prescription business maintained its No.2 position. ❖ Emerging Markets and Europe EMEU delivered revenue of $ 101 Mn during the quarter. The business operated in a challenging environment marked by geopolitical uncertainties and market-specific headwinds; however, it continued to demonstrate resilience through strong execution and cost discipline across both DTM and B2B segments. #Market data as per IQVIA, YTD Sep’26|*Market data as per IQVIA week ending 25th Sep’26 |** Market data as per IQVIA MAT Aug’26 QUARTERLY BUSINESS WISE SALES PERFORMANCE Y-o-Y Business (In INR Cr) Q2FY27 Q2FY26 Growth India (Rx + Gx + CHL^) 3,516 3,146 12% North America 1,643 2,039 -19% One Africa# 1,171 1,178 -1% South Africa 872 901 -3% Emerging Markets and Europe 967 967 0% API and Others 107 259 -59% Total 7,404 7,589 -2% ^ CHL – Cipla Health limited |# Includes South Africa, North Africa, Sub-Saharan Africa and Cipla Global Access CONSOLIDATED PROFIT & LOSS STATEMENT In INR Cr Q2FY27 Q2FY26 Total Income from Operations 7,404 7,589 EBITDA 1,388 1,895 % of Income from Operations 18.7% 25.0% PAT 878 1,351 BALANCE SHEET Key Balance Sheet Items (INR Cr) Sep-26 Sep-25 Equity 35,522 33,025 Total Debt# 699 467 Inventory 6,778 6,160 Cash and Cash Equivalents* 10,552 10,368 Trade Receivables 6000 6,902 Trade Payables 3,266 3,035 Net Tangible Assets 8,266 6,996 Goodwill and Intangibles 7,107 5,374 #Total debt includes lease liabilities and borrowings| * Cash & cash equivalents include current investments, fixed deposits, margin deposits and excluding unclaimed dividend balances Announcement Cipla to release Q2FY27 unaudited Financial Results on October 27, 2026 Date: 27th October 2026 • 1600 hrs IST – EARNINGS CONFERENCE CALL The Company will host an earnings conference call at 1600 hrs IST (1830 hrs SST/HKT, 1030 hrs GMT, 0630 hrs US ET), during which the leadership team will discuss financial performance and take questions. A transcript of the conference call will be available at www.cipla.com. Earnings Conference Call Dial-in Information Date and Time October 27, 2026 at 1600 – 1700 hrs IST 1830 – 1930 hrs SST/HKT 1030 – 1130 hrs GMT 0630 – 0730 hrs US ET Dial-in Numbers Universal Access Primary Access: (+91 22 6280 1562) (+91 22 7115 8387) Diamond pass link Click here to register Toll Free Number USA: 18667462133 UK: 08081011573 Hong Kong: 800964448 Singapore: 8001012045 ABOUT CIPLA LTD Established in 1935, Cipla is a global pharmaceutical company focused on agile and sustainable growth, complex generics, and deepening portfolio in our home markets of India, South Africa, North America, and key regulated and emerging markets. Our strengths in the respiratory, anti-retroviral, urology, cardiology, anti-infective and CNS segments are well-known. Our 46 manufacturing sites around the world produce 50+ dosage forms and 1,500+ products using cutting-edge technology platforms to cater to our 80+ markets. Cipla is ranked 3rd largest in pharma in India (IQVIA MAT Sep’26), 2nd Largest in the pharma prescription market in South Africa (IQVIA MAT Aug’26), and 2nd largest by prescription in the US Gx (Repulses + MDI) products (IQVIA MAT Sep’26). For over eight decades, making a difference to patients has inspired every aspect of Cipla’s work. Our paradigm-changing offer of a triple anti-retroviral therapy in HIV/AIDS at less than a dollar a day in Africa in 2001 is widely acknowledged as [Showing first 8,000 characters — download PDF for full document]